NEWS & Join Us

“The true sign of intelligence is not knowledge but imagination." — Albert Einstein

\

Tavotek Biotherapeutics to Attend 2022 San Antonio Breast Cancer Symposium

  • Author:
  • Origin:
  • Time of issue:2022-12-06
  • Views:3459

Tavotek Biotherapeutics to Attend 2022 San Antonio Breast Cancer Symposium

  • Author:
  • Origin:
  • Time of issue:2022-12-06
  • Views:3459

(LOWER GWYNEDD, Pennsylvania, December 6, 2022) Tavotek Biotherapeutics, a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing medicines for unmet medical needs, will attend the 2022 San Antonio Breast Cancer Symposium located in San Antonio, TX. 


Tavotek will showcase TAVO412, a novel multispecific antibody with unique 2:1:1 ratio of EGFR:cMet:VEGF binding arms with excellent activity against TNBC. 


About Tavotek


Tavotek Biotherapeutics is a multi-specific antibody drug company with the world's cutting-edge protein engineering technology, focusing on oncology and immunology diseases. The company's R&D is mainly built on three innovative breakthrough technology platforms, namely: TavoSelectTM, a bacteriophage biobank with AI assisted 3D selection; TavoPreciseTM, a sophisticated protein engineering platform that supports the development of bispecific and multi-specific antibodies, and TavoELITETM, an innovative synthetic biologic platform focusing on overcoming intracellular undruggable targets with particular focus on protein-protein interaction. With unique innovative R&D capabilities, biomarker-driven clinical development strategies, and efficient execution efficiency, Tavotek will provide treatment options with better efficacy, safety and convenience to advance medical care for patients.


Related News

NAVROGEN INC. AND TAVOTEK BIOTHERAPEUTICS ANNOUNCE STRATEGIC COLLABORATION TO IMPROVE THERAPEUTIC EFFICACY OF ANTIBODY PIPELINE AGENTS
Tavotek Biotherapeutics Attends The 41st Annual J.P. Morgan Healthcare Conference
NAVROGEN INC. AND TAVOTEK BIOTHERAPEUTICS ANNOUNCE STRATEGIC COLLABORATION TO IMPROVE THERAPEUTIC EFFICACY OF ANTIBODY PIPELINE AGENTS
Tavotek Biotherapeutics Announces FDA Clearance of FIH Clinical Trial for TAVO412
NAVROGEN INC. AND TAVOTEK BIOTHERAPEUTICS ANNOUNCE STRATEGIC COLLABORATION TO IMPROVE THERAPEUTIC EFFICACY OF ANTIBODY PIPELINE AGENTS
Tavotek Launching First-In-Human Study of Two Assets In 2022
NAVROGEN INC. AND TAVOTEK BIOTHERAPEUTICS ANNOUNCE STRATEGIC COLLABORATION TO IMPROVE THERAPEUTIC EFFICACY OF ANTIBODY PIPELINE AGENTS
Tavotek Biotherapeutics Doses First Patient in Phase 1 First-in-Human Clinical Trial of TAVO412, a Multispecific Biologic for Solid Tumors

727 Norristown Road, 3 Spring House Innovation Park Suite 101, Lower Gwynedd, Pennsylvania 19002

China. Suzhou. Suzhou Industrial Park. Unit 405, Building C2, No. 218, Xinghu Street

© 2023 Tavotek Biotherapeutics All rights reserved.   (267) 405-9426

© 2023 Tavotek Biotherapeutics All rights reserved.(267) 405-9426